Current and novel therapeutics in the treatment of systemic lupus erythematosus

J Allergy Clin Immunol. 2011 Feb;127(2):303-12; quiz 313-4. doi: 10.1016/j.jaci.2010.12.1087.


Systemic lupus erythematosus (SLE) is a complex autoimmune disease with significant clinical heterogeneity. Recent advances in our understanding of the genetic, molecular, and cellular bases of autoimmune diseases and especially SLE have led to the application of novel and targeted treatments. Although many treatment modalities are effective in lupus-prone mice, the situation is more complex in human subjects. This article reviews the general approach to the therapy of SLE, focusing on current approved therapies and novel approaches that might be used in the future.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Immunoglobulins, Intravenous / therapeutic use
  • Lupus Erythematosus, Systemic / drug therapy*
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Oligonucleotides / therapeutic use
  • Rituximab


  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Immunoglobulins, Intravenous
  • Oligonucleotides
  • epratuzumab
  • Rituximab
  • Hydroxychloroquine
  • belimumab
  • Cyclophosphamide
  • Mycophenolic Acid
  • abetimus